viral
dna
rna
npa
bal
sampl
analys
via
pcr
follow
virus
cytomegaloviru
cmv
adenoviru
adv
respiratori
syncyti
viru
rsv
b
influenza
viru
b
parainfluenza
viru
human
metapneumoviru
extend
viral
pcr
adopt
includ
rhinovirus
enteroviru
human
coronaviru
strain
human
leucocyt
antigen
hla
type
perform
molecular
type
hla
class
ii
loci
mismatch
defin
hla
ident
bone
marrow
peripher
blood
stem
cell
sourc
cord
blood
myeloabl
condit
includ
condit
receiv
mgkg
cumul
dose
total
bodi
regimen
receiv
gy
fraction
dose
diagnosi
acut
gvhd
made
clinic
confirm
patholog
skin
mucos
liver
biopsi
whenev
possibl
grade
acut
gvhd
perform
accord
seattl
criteria
martino
et
al
immun
reconstitut
evalu
absolut
count
total
lymphocyt
lymphocyt
subset
evalu
flow
cytometri
cell
month
transplant
signific
cmv
viru
ebv
adv
reactiv
consid
peripher
blood
viral
load
reach
iuml
copiesml
copiesml
respect
transplant
featur
demograph
characterist
includ
descript
statist
evalu
outcom
includ
overal
surviv
os
trm
day
hsct
defin
patient
complet
respons
deceas
day
procedur
progress
lower
respiratori
tract
infect
lrti
previous
defin
rate
admiss
icu
log
rank
test
perform
compar
surviv
curv
cumul
incid
trm
group
patient
univari
analysi
categor
variabl
use
fisher
exact
test
investig
risk
factor
final
outcom
variabl
show
signific
associ
outcom
univari
analysi
includ
logist
regress
model
multivari
analysi
threshold
signific
result
analysi
set
p
data
analysi
statist
perform
use
prism
graphpad
softwar
version
graphpad
softwar
inc
la
jolla
ca
usa
epi
center
diseas
control
prevent
atlanta
ga
usa
softwar
featur
patient
transplant
procedur
summar
tabl
studi
period
children
underw
allogen
hsct
procedur
one
patient
exclud
analysi
npa
sampl
collect
time
transplant
patient
refer
hsct
pid
haematolog
malign
prefer
stem
cell
sourc
bone
marrow
patient
fulli
relat
unrel
donor
median
age
patient
cohort
year
rang
small
proport
patient
sever
combin
immunodefici
scid
receiv
condit
prior
hsct
screen
npa
result
start
condit
regimen
avail
transplant
two
patient
investig
vri
time
transplant
monitor
earli
late
overal
patient
present
viral
pathogen
npa
transplant
three
patient
receiv
two
hsct
posit
npa
children
present
symptom
activ
upper
respiratori
tract
infect
urti
asymptomat
frequenc
differ
viral
infect
report
tabl
eight
patient
present
involv
two
virus
decis
delay
hsct
taken
case
found
posit
rsv
six
influenza
b
five
parainfluenza
virus
two
adv
final
one
metapneumoviru
howev
three
patient
clear
viral
infect
overal
patient
underw
hsct
activ
viral
urti
rhinoviru
parainfluenza
rsv
adv
influenza
ab
metapneumoviru
cmv
seven
patient
present
viral
coronaviru
rhinoviru
cmv
rhinoviru
parainfluenza
influenza
adv
rhinoviru
rsv
cmv
rsv
parainfluenza
transplant
patient
routin
screen
npa
week
admiss
hsct
follow
discharg
case
respiratori
symptom
suggest
urti
new
vri
document
within
first
year
tabl
children
respiratori
symptom
seven
patient
found
posit
two
virus
determin
coronaviru
virus
detect
day
month
transplant
although
infect
occur
within
first
day
transplant
median
time
npa
posit
day
half
new
vri
occur
first
day
transplant
earli
infect
patient
urti
within
first
year
hsct
diagnos
lrti
document
posit
bal
case
posit
npa
patient
frequent
viru
respons
lrti
parainfluenza
viru
follow
rsv
three
patient
experienc
two
virus
patient
lrti
due
pathogen
detect
screen
admiss
picu
necessari
patient
respiratori
failur
overal
patient
diagnos
lrti
die
tabl
si
two
case
caus
attribut
vri
mortal
significantli
higher
rate
lrti
observ
patient
posit
npa
prior
transplant
compar
experienc
new
urti
transplant
vs
odd
ratio
p
moreov
patient
activ
infect
requir
picu
admiss
frequent
vs
confid
interv
ci
p
fig
earli
infect
day
day
late
infect
day
equal
contribut
lrti
vs
p
children
neg
npa
overal
surviv
os
cohort
trm
stratifi
surviv
rate
accord
four
differ
group
patient
undergo
transplant
posit
npa
patient
newli
posit
npa
transplant
patient
neg
npa
transplant
group
patient
whose
transplant
delay
due
posit
npa
clear
viru
condit
found
statist
higher
surviv
rate
patient
delay
hsct
start
condit
regimen
resolv
vri
os
compar
patient
start
condit
activ
vri
os
hazard
ratio
hr
ci
p
fig
signific
differ
os
note
delay
group
patient
diagnos
new
respiratori
infect
transplant
experi
vri
respect
p
also
evalu
stratif
trm
group
patient
fig
children
present
posit
npa
screen
time
transplant
significantli
higher
trm
hr
ci
p
signific
differ
earli
mortal
observ
patient
new
vri
vri
time
transplant
due
delay
procedur
occurr
respiratori
infect
consid
patient
posit
npa
deceas
patient
caus
death
attribut
vri
two
die
fungal
pneumonia
one
lung
microangiopathi
overal
mortal
higher
patient
activ
urti
children
npa
posit
transplant
vs
hr
ci
p
fig
order
evalu
impact
differ
risk
factor
patient
die
due
transplant
complic
first
day
hsct
trm
progress
lrti
perform
univari
analysi
differ
variabl
tabl
npa
posit
time
transplant
signific
risk
factor
earli
mortal
relat
transplant
complic
well
use
umbil
cord
blood
ucb
stem
cell
sourc
use
hla
mismatch
donor
multivari
analysi
npa
posit
use
hla
mismatch
donor
independ
associ
earli
trm
tabl
also
investig
impact
rhinoviru
infect
outcom
fig
earli
trm
lower
patient
npa
posit
rhinoviru
compar
patient
vri
start
condit
although
reach
signific
p
howev
differ
note
patient
neg
npa
trm
p
univari
analysi
risk
progress
lrti
significantli
higher
children
posit
npa
tabl
viral
respiratori
infect
repres
major
caus
morbid
mortal
hsct
possibl
evolut
respiratori
failur
lack
effect
therapeut
strategi
avail
screen
respiratori
virus
routin
perform
bone
marrow
transplant
bmt
unit
presenc
urti
univers
recognis
risk
factor
merit
transplant
delay
extens
analys
outcom
patient
posit
npa
screen
hsct
period
found
viral
infect
profound
impact
clinic
outcom
lead
lower
os
higher
trm
compar
patient
experienc
de
novo
viral
infect
hsct
activ
viral
infect
time
transplant
neg
influenc
outcom
patient
experienc
respiratori
mortal
almost
case
signific
proport
children
includ
cohort
affect
pid
patient
could
suscept
recurr
difficult
erad
viral
rti
howev
result
increas
preval
vri
compar
literatur
inde
campbel
et
al
report
higher
preval
posit
respiratori
viru
screen
especi
children
howev
studi
minor
patient
year
old
note
studi
higher
mortal
rate
children
viral
infect
also
report
compar
adult
studi
newli
occur
vri
mainli
document
earli
phase
hsct
preval
compar
one
recent
describ
children
receiv
hsct
fisher
et
al
interestingli
studi
earli
infect
within
first
day
transplant
associ
higher
morbid
mortal
support
crucial
impact
immun
statu
outcom
patient
rvi
main
complic
relat
viral
urti
progress
lrti
show
start
condit
activ
upper
airway
respiratori
infect
lead
frequent
pulmonari
involv
irrespect
background
diagnosi
hla
match
occurr
gvhd
use
ucb
partial
associ
higher
rate
lrti
could
relat
lower
cell
dose
delay
lymphocyt
engraft
nichol
et
al
kim
et
al
interestingli
higher
rate
intens
care
need
patient
posit
npa
screen
also
observ
importantli
children
delay
transplant
present
similar
background
featur
npa
transplant
patient
reduc
earli
mortal
transplant
compar
patient
delay
transplant
despit
activ
viral
infect
document
admiss
differ
unlik
reflect
select
bia
better
risk
patient
look
earli
trm
progress
lrti
main
caus
graft
failur
npa
group
three
patient
die
due
pulmonari
complic
accordingli
risk
factor
analysi
show
posit
npa
major
risk
factor
earli
mortal
sever
clinic
cours
patient
respiratori
viru
document
upper
airway
transplant
could
relat
younger
age
patient
given
age
year
associ
dismal
outcom
vri
el
saleebi
et
al
howev
patient
experienc
viral
infect
transplant
significantli
older
median
age
year
european
guidelin
provid
weak
recommend
postpon
condit
case
vri
hirsch
et
al
transplant
delay
controversi
patient
postpon
procedur
eg
patient
affect
aggress
malign
disord
present
immunolog
compet
clear
viru
eg
patient
scid
nevertheless
case
influenza
rsv
infect
delay
hsct
allow
pharmacolog
treatment
ie
oseltamivir
ribavirin
respect
unfortun
virus
effect
treatment
avail
viral
clearanc
depend
efficaci
host
immun
system
especi
patient
pid
frequent
present
chronicrefractori
vri
balanc
riskbenefit
ratio
challeng
viral
clearanc
unlik
scid
patient
occur
presenc
residu
cell
immun
one
studi
report
efficaci
transplant
delay
adult
children
rsv
urti
condit
show
surviv
significantli
improv
compar
encount
viru
transplant
peck
et
al
whether
postpon
hsct
posit
npa
rhinoviru
debat
sinc
lrti
progress
frequent
howev
lower
airway
infect
transplant
lead
worsen
outcom
seo
et
al
mowrer
et
al
howev
data
although
retrospect
limit
small
cohort
patient
show
rhinoviru
infect
associ
modestli
lower
trm
compar
viral
strain
involv
urti
overal
compar
patient
neg
npa
screen
transplant
delay
feasibl
strategi
aim
improv
lymphocyt
recoveri
first
week
transplant
eg
target
vivo
deplet
admira
et
al
adopt
immunotherapi
ciceri
et
al
consid
faster
immun
reconstitut
usual
expect
vivo
deplet
omit
administ
earli
condit
lindeman
et
al
gvhd
prophylaxi
alemtuzumab
result
delay
lymphocyt
recoveri
compar
globulin
shah
et
al
decis
regard
vivo
deplet
strategi
balanc
risk
gvhd
versu
burden
activ
viral
infect
ex
vivo
manipul
graft
select
deplet
alloreact
cell
allow
presenc
gammadelta
cell
graft
tackl
infect
bertaina
et
al
locatelli
et
al
cell
induc
dimer
also
develop
zhou
et
al
final
condit
regimen
could
limit
organ
toxic
allow
transplant
also
patient
sever
infect
ie
pid
patient
although
risk
engraft
failur
activ
viral
infect
contempl
howev
prospect
data
necessari
evalu
impact
vivo
ex
vivo
deplet
vri
recommend
best
strategi
made
retrospect
studi
largest
paediatr
hsct
centr
uk
show
screen
vri
prior
transplant
paramount
import
outcom
dismal
patient
transplant
posit
npa
screen
moreov
patient
delay
hsct
clearanc
vri
improv
outcom
suggest
screen
strategi
reduc
trm
prospect
studi
need
explor
novel
strategi
treat
viral
infect
children
elig
hsct
work
receiv
fund
jb
receiv
fund
ucluclh
nihr
biomed
research
centr
author
declar
conflict
interest
go
rc
design
studi
analys
data
wrote
manuscript
kr
pa
gl
pv
interpret
result
critic
review
manuscript
jsf
jb
oc
al
review
manuscript
author
review
approv
manuscript
